

STUDY ON EVALUATION OF THERAPEUTIC EFFECT OF *BACOPA-MONNIERI* ON CEREBELLAR TOXICITY CAUSED BY ARSENIC AND NICOTINE IN MALE SPRAGUE-DAWLEY RATS

THESIS SUBMITTED

TO

**SRI DEVARAJ URS ACADEMY OF
HIGHER EDUCATION AND RESEARCH**



**For Awarding the Degree as
DOCTOR OF PHILOSOPHY
IN MEDICAL ANATOMY**

Under Faculty of Medicine

By

RAVI SHANKAR PRASAD SAWAN

Under the Supervision of

Dr. (Prof.) SRIDEVI N.S



**Department of Anatomy
Sri Devaraj Urs Medical College
A Constituent of
Sri Devaraj Urs Academy of Higher Education and Research
Tamaka, Kolar, Karnataka 563103**

October 2022

DECLARATION BY CANDIDATE


Ravi Shankar Prasad Sawan
Registration No.: 18PY1002
Department of Anatomy
Sri Devaraj Urs Medical College,
Tamaka, Kolar, Karnataka-563103
India

Email: ravisawan1990@gmail.com
Mobile No. +91-7204468983

I 'Ravi Shankar Prasad Sawan' do hereby declare that the thesis entitled "**Study on evaluation of therapeutic effect of *Bacopa-Monnieri* on Cerebellar toxicity caused by Arsenic and Nicotine in Male Sprague-Dawley Rats**" embodies original research work carried out by me for the award of **Doctor of Philosophy** in Medical Anatomy under Supervision of **Dr. Sridevi NS**, Professor and Head, Department of Anatomy and Co-supervision of **Dr. Shashidhar KN**, Professor and Head, Department of Biochemistry, Sri Devaraj Urs Medical College, A Constituent of Sri Devaraj Urs Academy of Higher Education and Research, Tamaka, Kolar, Karnataka, India.

This work has not been submitted in part or full for any other degree or diploma of this or any other Universities. The particulars given in this thesis are true to the best of my knowledge.

Date: 27-10-2022



(Ravi Shankar Prasad Sawan)

Place: SBUCMC, Kolar

CERTIFICATE


This is to certify that the thesis entitled "Study on evaluation of therapeutic effect of *Bacopa-Monnieri* on Cerebellar toxicity caused by Arsenic and Nicotine in Male Sprague-Dawley Rats" submitted for the requirement of award of Degree, Doctor of Philosophy by **Mr. Ravi Shankar Prasad Sawan (Reg. No. 18PY1002)** is the record of original research work carried out by him under supervision of **Dr. Sridevi NS**, Professor and Head, Department of Anatomy and Co-Supervision of **Dr. Shashidhar KN**, Professor and Head, Department of Biochemistry, Sri Devaraj Urs Medical College, A constituents of Sri Devaraj Urs Academy of Higher Education and Research, Tamaka, Kolar, Karnataka, India.

This research work included in the thesis has not been submitted for the award of any degree, diploma, associateship, fellowship or other similar titles in this universities or any other Universities of Institution of Higher learning.


Signature of Supervisor
Professor & Head
Department of Anatomy
SDUMC, Kolar.

Dr. Sridevi NS
Professor and Head
Department of Anatomy
Sri Devaraj Urs Medical College,
Sri Devaraj Urs Academy of Higher Education and Research
Tamaka, Kolar, Karnataka, India


Signature of Co-supervisors


Dr. Shashidhar KN
Professor and Head
Department of Biochemistry
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research
Tamaka, Kolar, Karnataka, India

CERTIFICATE


This is to certify that the thesis entitled "Study on evaluation of therapeutic effect of *Bacopa-Monnieri* on Cerebellar toxicity caused by Arsenic and Nicotine in Male Sprague-Dawley Rats" submitted for the requirement of award of Degree, Doctor of Philosophy by Mr. Ravi Shankar Prasad Sawan (Reg. No. 18PY1002) is the record of original research work carried out by him under supervision of Dr. Sridevi NS, Professor and Head, Department of Anatomy and Co-Supervision of Dr. Shashidhar KN, Professor and Head, Department of Biochemistry, Sri Devaraj Urs Medical College, A constituents of Sri Devaraj Urs Academy of Higher Education and Research, Tamaka, Kolar, Karnataka, India.

No part of this thesis has been previously formed the basis for the award of any degree or fellowship.


Signature of the HOD
Professor and Head
Department of Anatomy
SDUMC, Kolar.

Dr. Sridevi NS
Professor and Head
Department of Anatomy
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research
Tamaka, Kolar, Karnataka

Signature of the Principal/ Dean Faculty of Medicine


Principal
Dr. PN Sreenamulu
Sri Devaraj Urs Medical College
Tamaka, Kolar-585103.
Sri Devaraj Urs Academy of Higher Education and Research
Tamaka Kolar, Karnataka

Certificate

This is to certify that the project **Study on evaluation of therapeutic effect of Bacopa Monnieri on cerebellar toxicity caused by Arsenic and Nicotine on Sprague - Dawley Rats.** (IAEC/PHARMA/SDUMC/2018-19/12a) has been approved by the IAEC.

Approved Sixty Four Rats

Name of Chairman/ Member Secretary IAEC:

Name of CPCSEA nominee:

Signature with date

P. N. I. R.
21.6.19
Principal

Sri Devaraj Urs Medical College

Chairman/ Member Secretary of IAEC:

P. Krishnamoorthy
21/6/19

Dr. P. Krishnamoorthy, Ph.D.

Dr. P. Krishnamoorthy, Ph.D.
Senior Scientist / Senior Scientist

CPCSEA nominee:

(Kindly make sure that minutes of the meeting duly signed by all the participants are maintained by Office)



UNIVERSITY OF AGRICULTURAL SCIENCES, BENGALURU

Dr. A. N. Sringeswara
Curator

Mahatma Gandhi Botanical Garden
GKVK Campus, Bengaluru - 560 065

Date: 15-09-2020

Authentication Certificate

This is to certify that the plant specimen brought for identification collected by Ravi Shankar Prasad Sawan is identified as *Bacopa monnieri* (L.) Wettst. (Plantaginaceae) and given the accession number UASB4608.

To,

Ravi Shankar Prasad Sawan
Ph. D. Scholar (Dept. of Anatomy)
Sri Devaraja Urs Medical College, Kolar



(A. N. SRINGESWARA)

Dr. A. N. Sringeswara
Curator

Mahatma Gandhi Botanical Garden
University of Agricultural Sciences
GKVK Campus, Bengaluru-65.



Sri Devaraj Urs Academy of Higher Education and Research

Certificate of Plagiarism Check for Thesis

Author Name	RAVI SHANKAR PRASAD SAWAN
Course of Study	Ph.D.
Name of Guide	Dr. Sridevi N S
Department	Anatomy
Acceptable Maximum Limit	10%
Submitted By	librarian@sduaher.ac.in
Paper Title	STUDY ON EVALUATION OF THERAPEUTIC EFFECT OF BACOPA-MONNIERI ON CEREBELLAR TOXICITY CAUSED BY ARSENIC AND NICOTINE IN MALE SPRAGUE-DAWLEY RATS
Similarity	8%
Paper ID	641564
Submission Date	2022-10-25 04:30:14

Ravi Shankar
Signature of Student
25-10-2022

Sridevi N S
Signature of Guide
Prof. Dr. Sridevi N S
Department of Anatomy
SDUMC, Kolar.

[Signature]
University Librarian
University Library
Learning Resource Centre
SQUAHER, Tamaka
KOLAR

Sridevi N S
Head of the Department
Prof. Dr. Sridevi N S
Department of Anatomy
SDUMC, Kolar.

This report has been generated by DrillBit Anti-Plagiarism Software

ACKNOWLEDGEMENT

At this juncture, I come to the notion that this work is the result of wholehearted cooperation of the well-wishers and grace of Almighty God.

This thesis arose in part out of years of research that has been done since I came to Sri Devaraj Urs Medical College (SDUMC), Tamaka, Kolar, Karnataka, India. By this time, I have worked with a great number of people whose contribution in assorted ways to the research and the making of the thesis deserved special mention. It is a pleasure to convey my gratitude to the following persons for their dedication, prayers and support in my humble acknowledgment.

*It is my privilege to express my sincere regard and deep sense of gratitude to my honorable research supervisor **Dr. Sridevi NS**, Prof. and Head, Department of Anatomy, Sri Devaraj Urs Medical College, Tamaka, Kolar, Karnataka (Sri Devaraj Urs Academy of Higher Education and Research) for her valuable guidance, enlightening discussions, critical comments and constant encouragement which enabled me to bring out a satisfactory shape of my thesis.*

*I express my infinite indebtedness and profound gratitude to my Co-supervisor **Dr. Shashidhar KN**, Professor and Head, Department of Biochemistry, Sri Devaraj Urs Medical College, Tamaka, Kolar, Karnataka, for his guidance, help, unfailing patience and encouragement throughout my work and also permitting to use the facilities of the Department during this work.*

*It gives me pleasure to thank Honorable Chancellor **Shri G.H. Nagaraja**, Honorable Vice Chancellor **Dr. Pradeep Kumar Goud**, and respected Registrar **Dr. D.V.L.V Prasad** of SDUAHER for their support.*

*I convey my sincere thanks to **Dr. P.N. Sreeramulu**, Professor, Department of Surgery, Principal and Dean, Faculty of Medicine, Sri Devaraj Urs Medical College, Tamaka, Kolar for his support and encouragement.*

*I am thankful to all the faculties who guided me in Research Methodology classes during the first 6 months of PhD. I am thankful to Ph. D. Coordinator **Dr. Sharath B**, Assoc. Professor and Head, Department of Cell Biology & Molecular Genetics for his support in processing our progress report.*

*I wish to express my deep acknowledgement to **Dr. Sarala**, Professor, Department of Pharmacology, Director of Academics, SDUAHER for providing Animal House to carry out this experiment.*

*I pay my sincere thanks to **Dr. Muninarayana** and **Dr. T. Govindappa**, Veterinarian, Teaching faculties **Dr. Bhuvana** and **Dr. Harish** and Non-Teaching faculties **Mr. Ramesh**, **Mr. Srinivasa**, Department of Pharmacology, SDUMC for their help.*

*I would like to extend my indebtedness to **Mr. Ravi Shankar**, Statistician, Department of Community Medicine, for his valuable suggestion and encouragement during data analysis.*

*I am grateful to my doctoral committee member, **Dr. Varsha Mokhasi**, Professor and Head Department of Anatomy, Vydehi Institute of Medical Sciences & Research Centre, Bengaluru, for her inputs during Doctoral committee presentation.*

*I wish to thank **Dr. Dhananjay** and **Dr. Anil**, College of Horticulture, Kolar for his kind assistance in this work.*

*I convey my sincere thanks to **Dr. Chandraprasad S**, BMS College of biotechnology, Bangalore, for his support.*

*My sincere appreciation also goes to pathology lab technician **Mrs. Asha**, **Mr. Birendra** and **Mr. Gowri Shankar** for their assistance in doing sectioning.*

*I also acknowledge with thanks all sorts of help and cooperation received from **Dr. Prakash**, Librarian, Sri Devaraj Urs Medical College, Tamaka, Kolar for his timely assistance.*

*I am thankful for all the teaching faculty and Ph.D. Scholars, Department of Anatomy **Dr. Venkateshu KV**, **Dr. Ashwini NS**, **Dr. Divya**, **Dr. Shashidhar**, **Dr. Vinay Kulkarni**, **Mr. Suresh T**, **Dr. Kumarswamy**, **Dr. Krishnaveni**, **Dr. Krishna Kishore**, **Dr. Bhuneshwar Yadav**, **Dr. Suresh Konakunchi**, **Dr. Anjaneyababu Naik** and **Mr. Amalesh Kumar Yadav** for their encouragement, support, help and advice during my research.*

*I thank all the technical and non-technical staff of our department **Mr. Arun**, **Mr. Chalapati**, **Mr. Narayanappa**, **Mr. Chandrappa**, **Mrs. Sowbhagyamma**, **Mrs. Bharathi** and **Mrs. Priya**.*

I take this opportunity to thank my family members and relatives, who have encouraged me throughout my Ph.D. work to realize how important knowledge is and how one can

*contribute to the society as a whole howsoever in a small way possible to the best of one's ability. Last but not the least; my deepest gratitude goes to my parents **Mr. Ram Ashish Yadav** and **Mrs. Mantutiya Devi**, my elder brother **Mr. Ram Shankar Yadav** and Sister-in-law **Mrs. Renu Yadav** who are the priceless source of love, support and encouragement during the most tiring phases of my work, which has enabled me to complete my work. But for their keenness and interest, the task I undertook could have been much harder to achieve within the strict time frame.*

*Words are not enough to express my sincere thanks to my beloved nephew **Rishiraj Adhikary**, Niece **Mrs. Rishika Yadav** and Cousin **Saroj Kumar Yadav** for all their love, encouragement and support by just being there for me.*

My sincere thanks are tendered to a great number of unmentioned friends, relatives, dear and near ones and well-wishers for all the care, encouragement and moral support.

Above all, I bow my head before God-The Almighty who gave blessings, mental courage, physical fitness and patience for successfully completing this work.

Ravi Shankar Prasad Sawan

LIST OF ABBREVIATIONS

CNS	Central Nervous System
PNS	Peripheral Nervous System
As	Arsenic
Ni	Nicotine
<i>BM</i>	<i>Bacopa-Monnieri</i>
WHO	World Health Organization
BBB	Blood Brain Barrier
MCL	Maximum contaminant limit
PCs	Purkinje cells
ROS	Reactive Oxygen Species
iAs	Inorganic Arsenic
nAChRs	Nicotinic acetylcholine receptor
IUCN	International Union for Conservation of Nature
As ₂ O ₃	Arsenic trioxide
PPM	Parts per million
NaAsO ₂	Sodium Arsenite
AsCl ₃	Arsenic trichloride
As ₂ O ₅	Arsenic pentoxide
PbHAsO ₄	lead arsenate
OFT	Open Field Test
EPM	Elevated Plus Maze
BWT	Beam Walking Test
H & E	Hematoxylin and Eosin
DPX	Dibutylphthalate polystyrene xylene
NRT	Nicotine replacement therapy
HP	Hydrogen Peroxide
MeHg	Methylmercury
LPP	Lipid peroxidation product
BME	Extract of <i>Bacopa-Monnieri</i>
IAEC	Institutional Animal Ethics Committee
PBS	Phosphate Buffer solution

CPCSEA	Committee for the Purpose of Control and Supervision of Experiments on Animals
HPLC	High Performance Liquid Chromatography
AAS	Atomic Absorption Spectrophotometry
MDA	Malondialdehyde
NO	Nitric-Oxide
GPx	Glutathione Peroxidase
LPO	Lipid Peroxidation
HNO ₃	Nitric-acid
GSH	Reduced Glutathione
EDTA	Ethylene diamine tetra-acetic acid
HClO ₄	Perchloric acid
TCA	Trichloro-Acetic Acid
TBARS	Thiobarbituric Acid Reactive Substances
μl	Microliter
μg	Microgram
%	Percentage
SD	Standard Deviation
RPM	Revolutions per minute
μm	Micrometer/micron

LIST OF TABLES

Table No.	Title	Page No.
1	Physical and chemical properties of arsenic	16
2	Physical and chemical properties of nicotine	26
3	Classification of <i>Bacopa-Monnieri</i>	38
4	Chemical composition of <i>Bacopa-Monnieri</i>	39
5	Signs and symptoms used to determine if each rat was ill and therefore ineligible for participation in the study	46
6	Preliminary phytochemical screening of crude form of <i>Bacopa-Monnieri</i>	82
7	Physical and physiological observations in comparison with Group I	85
8	Body weight of rats.	87
9	Brain weight of rats	88
10	Arsenic concentration in serum and cerebellar tissue of rats	89
11	Nicotine concentration in Serum and Cerebellar tissue of rats.	90
12	Serum oxidative stress parameters (MDA, NO and GPx)	92
13	Cerebellar tissue oxidative stress parameters (MDA, NO and GPx)	94
14	A: Open Field test.	97
	B: open field test	98
15	A: Elevated plus maze	103
	B: Elevated plus maze	104
16	Beam walking test (2.5cm thick Beam)	106
17	Beam walking test (5 cm thick Beam)	108
18	Morphometry of Purkinje cell of cerebellum	111
19	Thickness of layers of cerebellum	116

TABLE OF CONTENTS

SL.NO.	TITLE	PAGE NO.
1	INTRODUCTION	1-10
2	REVIEW OF LITERATURE	11-42
3	OBJECTIVES	43
4	MATERIALS AND METHODS	44-80
5	RESULTS	81-116
6	DISCUSSION	117-130
7	NEW KNOWLEDGE GENERATED	131
8	CONCLUSION	132-133
9	LIMITATIONS	134
9	RECOMMENDATION	135
10	REFERENCES	136-162
11	PUBLICATION/PRESENTATION	ANNEXURE I

PICTORIALS

Figure No.	Title	Page No.
1	Overview of Histology of cerebellum	14
2	Arrangement of neurons in cerebellar cortex	14
3	Arsenic metabolism showing arsenate reduction to arsenite and methylation to pentavalent and trivalent forms.	19
4	Structure of Nicotine (C ₁₀ H ₁₄ N ₂)	25
5	Metabolism of nicotine	31
6	Administration of drugs through oral gavage in male Sprague-Dawley rat	48
7	Chemical (Arsenic and Nicotine) and <i>Bacopa-Monniери</i> induced in rats.	50
8	Overview of experimental methodology	51
9	Open Field Arena	57
10	Elevated plus Maze	59
11	Beam Walking Test	61
12	Glass Teflon homogenizer for tissue homogenization	62
13	HPLC equipment with reagents	72
14	Steps of tissue sectioning	75
15	Phytochemical screening of crude from of <i>Bacopa-Monniери</i>	81
16	Purkinje cell linear density.	111
17	Morphology of Purkinje cells (Perimeters and Diameters)	112
18	Thickness of layers of cerebellum	115

GRAPHS

Graph No.	Title	Page No.
1	Standard Graph for Malondialdehyde (MDA)	65
2	Standard Graph for Nitric Oxide (NO)	68



Introduction

“We are what our nervous system permits” that means our thoughts, feelings, emotions, sensations, desires, dreams, ideas, creative urges, language and life itself are under the control of the most complex structure in the world – **The Nervous System**. The functions of more than 100 billion neurons constituting the nervous system are one of the mysteries of science. The nervous system is a complex collection of nerves and specialized cells called as neurons which transmit the signals between different parts of the body [1]. Sensory nerves gather information from the environment; send that information to spinal cord, which then sends a speed message to the brain. Motor neurons deliver the instructions from the brain to the rest of our body and adjust the body to the surroundings and regulate all bodily activities both voluntary and involuntary [2].

The Nervous system is commonly partitioned in two parts: the **Peripheral Nervous System (PNS)** and the **Central Nervous System (CNS)**. PNS merges into the CNS. So, dividing the Nervous system in two separate parts but in actual, these two interacting and communicating systems are a continuous entity. Together, the CNS and PNS control every part of our daily life, from breathing and blinking to learning and remembering, the way we walk and talk and it also control the things that we are less aware of - like beating of heart and digestion of food [2].

Furthermore, The CNS is usually subdivided into **Brain** (lies in cranial cavity) and **Spinal Cord** (lies in upper 2/3rd of the vertebral canal). The brain is again subdivided into three main parts:

1. Prosencephalon (Forebrain)

- a) Telencephalon: Cerebrum
- b) Diencephalon: Thalamus, hypothalamus, metathalamus, subthalamus and epithalamus

2. Mesencephalon (Midbrain): Crus cerebri, Substantia nigra, tectum and tegmentum

3. Rhombencephalon (Hindbrain)

a) Metencephalon: Pons and cerebellum

b) Myelencephalon: Medulla oblongata

The cerebellum (Latin word means little brain) is a part of hindbrain situated in posterior cranial fossa behind the pons, medulla oblongata and fourth ventricle and separated from occipital lobe of cerebrum by tentorium cerebelli. It is somewhat ovoid in shape. It weighs about 150 grams in male, forms $1/10^{\text{th}}$ part of cerebrum in adult and $1/20^{\text{th}}$ part in infants [3]. Cerebellum develops from the dorsolateral part of alar lamina of the metencephalon [4]. It helps in regulation and co-ordination in movement, posture and balance [5]. However, numbers of anatomical, physiological, clinical and neuro-imaging studies have shown that the cerebellum has extensive connections with the cerebral networks which may also play a role in neuro-cognition [6-9].

Cerebellar dysfunction causes ataxia, dysmetria, dyssynergia and disdiadikinesis of voluntary movement, disorders of gait and equilibrium, disorders of speech and abnormal ocular movements [10,11]. Diseases involving the cerebellum occur relatively common in children and adults around the globe. The prevalence rate of cerebellar ataxia is 26/100,000 in children, a prevalence rate of dominant hereditary cerebellar ataxia of 2.7/100,000 and a prevalence rate of recessive hereditary cerebellar ataxia of 3.3/100,000 [12].

CEREBELLAR TOXICITY:

There are a wide variety of causes for cerebellum neurotoxicity and leads to cerebellar ataxia [13, 14, 15].

1. Nutritional deficiencies

- a) Thiamine deficiency
- b) Vitamin B12 deficiency
- c) Vitamin E deficiency
- d) Zinc deficiency (rarely).

2. Infections

- a) **Acute cerebellitis** (Epstein-Barr virus, influenza A and B, mumps, varicella-zoster, coxsackie virus, rotavirus, echovirus, Mycoplasma and immunization
- b) **Bacterial:** Meningo-encephalitis or intracranial abscess, Mycoplasma pneumoniae, Listeria monocytogenes
- c) **Viral:** acute infections (eg, varicella); chronic infections - eg, human immunodeficiency virus (HIV); post-viral syndromes (eg, post-infective cerebellar syndrome in childhood)
- d) **Parasitic:** (eg. toxoplasma, falciparum malaria, Lyme disease)
- e) **Other infectious** (Lyme disease, Whipple disease, Aspergillus, JC virus, syphilis and Creutzfeldt-Jakob disease)

3. Toxins:

- a) Alcohol
- b) Environmental Heavy metals (mercury, lead, **Arsenic**, manganese, aluminium, thallium, germanium, uranium, vanadium)
- c) Solvents

- d) carbon-monoxide poisoning

4. Structural and vascular causes:

- a) Cerebellar stroke (ischemic and hemorrhagic)
- b) Tumors (primary and metastasis), Abscesses

5. Drugs:

- a) Anticonvulsants drugs (phenytoin, carbamazepine etc.)
- b) Antineoplastic drugs (methotrexate, capecitabine, epothilone D) and
- c) Other drugs (lithium salts, amiodarone, procainamide, bismuth, mefloquine, cimetidine, metronidazole, **Nicotine**)

6. Drug abuse and addiction:

- a) Cocaine
- b) Heroin
- c) Phencyclidine
- d) Methadone

7. Drug overdose:

- a) Accidental temazepam overdose in children

8. Trauma

9. Multiple sclerosis

10. Congenital

11. Paraneoplastic cerebellar degeneration

12. Insecticides/herbicides

ARSENIC:

In 21st century world, increasing industrialization of societies, expansion of factories, agricultural activities and burning of fossil fuels has dramatically increased

the amount of pollutants and environmental pollution. Environmental pollution is the world's greatest problem facing humanity and the leading environmental causes of morbidity and mortality. In 2015, it was reported that ill-health caused by environmental pollution accounted for 9 million premature deaths, which is more than three times the number of deaths from malaria, AIDS and tuberculosis put together [16].

Of all the types of pollution, contamination due to heavy metals and metalloids such as lead (Pb), cadmium (Cd), methylmercury (MeHg) and arsenic (As) are wide spread [17]. Among these heavy metals, environmental pollution due to arsenic is a major toxin and has become a major public health challenge in many countries such as Bangladesh, India, Nepal, Taiwan, Mongolia, Vietnam, Pakistan, China, Afghanistan, Argentina and USA [18]. Arsenic is released to the environment from anthropogenic sources such as mining wastes, metal smelting, wood preservatives, glass and semiconductor manufacture, pesticides and herbicides production [19]. Due to its increasing production and utilization, arsenic is ubiquitously present in water, air and soil affecting occupational workers as well as general population [20]. For the general population, arsenic in drinking water is the main exposure source and more harmful than arsenic in food because the bioavailability (actual amount absorbed into the bloodstream) of arsenic from water is greater than that from grains or vegetables [21]. Arsenic in drinking water is mainly inorganic arsenic which is more toxic than organic arsenic.

Arsenic primarily enters into the body through direct consumption of drinking water from geological deposits by drilling of tube well [22]. WHO and other regulatory bodies have established a maximum contaminant limit (MCL) of 10µg/L inorganic arsenic (iAs) in drinking water for the safety of human health based on

reducing cancer risk, but this limit is not considered as an endpoints for other cancers [23]. Globally, more than 200 million people are affected by ground water contaminated with arsenic concentration greater than 10 μ g/L [24]. During recent years, in comparison to others, China and India have become the most affected countries with serious diseases and the largest number of victims seen in hospitals due to arsenic poisoning [25]. In India, 7 states are reported to be affected by ground water arsenic contamination, and approximately 30 million individuals are consuming arsenic laden drinking water [26].

Numerous experimental and epidemiological studies provide evidence that acute and chronic arsenic exposure has been linked with numerous chronic indices in all human and animal organ systems and contributes to a wide spectrum of diseases especially disease involving CNS [27,28,29].

Arsenic crosses the Blood Brain Barrier (BBB) and accumulates in different regions of the brain and causes neurotoxicity [30]. The neurotoxicity of arsenic is widely noticed since arsenic exposure have shown various neurological side effects such as vertigo, sleep disorder, impaired coordination of movements, uncontrolled motor learning, loss of skilled voluntary movements, impaired learning, memory and concentration [31,32]. Brain is the first target organ for arsenic toxicity causing oxidative stress which increases the release of free radicals in brain leading to apoptosis of neural cells [18]. Arsenic induced toxicity causes morphological, structural and pathological changes in the brain [33]. Reports in the literature also document that arsenic treated rats reduces neuronal viability in primary cultures of rat cerebellar neurons and showed alterations in locomotor behavior and learning task [34,35]. These literatures indicate that cerebellum can be affected by arsenic.

NICOTINE:

Tobacco use is world's most serious problem, with substantial effect on human health and economic consequences. Tobacco exposure in any form (by inhalation of second hand tobacco smoker or comes in contact with the spit of oral smokeless tobacco users or with tobacco leaves during farming or manufacturing) kills and sickens millions of people every year [36]. Every year, Smoking related diseases causes more death than any other diseases (such as HIV, illegal drugs and alcohol use, motor vehicle accidents and murders combined) [37,38]. It is also a major contributor to morbidity, reducing fertility and increased risk of most cancers, coronary heart disease, diabetes and countless health complications [39].

Tobacco and tobacco smoke contains more than 9000 chemicals. Many of which are toxic and carcinogenic [40]. The tobacco alkaloid 'Nicotine' is considered as the major addictive component and toxic alkaloid compound in tobacco smoke and found primarily in the roots and leaves of solanaceous plant family where it constitutes approximately 0.60-3.00% of dry weight of tobacco [41,42]. There are different routes to get exposed with nicotine including cigarette smoking, chewing tobacco, holding moist snuff in the mouth, inhaling dry snuff through the nose, inhaling smoke from a water pipe and inhaling vapor from an electronic cigarette [43,44,45,46].

Nicotine exhibits protective activity towards several diseases such as Alzheimer's and Parkinson's diseases [47]. It was also used to treat nicotine dependence to eliminate smoking or minimize addiction and the damage it does to the health by providing controlled level of nicotine to the patient through gums, dermal patches, lozenges, inhalers or nasal sprays [48]. However, with extensive consumption, nicotine produces various detrimental roles on different systems of the

body such as cardiovascular system, respiratory system, gastrointestinal system, reproductive system, especially the Nervous System and triggers pathophysiology of brain and causes neurodegeneration. Exposure of the experimental animals to nicotine elicits oxidative stress and histological changes due to impairment in the brain's structural integrity and function [49, 50, 51].

By cigarette smoke or tobacco chewing, nicotine enters into the body through absorption in mucosal lining of mouth, nose and alveoli of lung. From the lungs, nicotine mixes into the bloodstream and rapidly enters into the brain by crossing Blood Brain Barrier (BBB) within 10-20 seconds, faster than intravenous administration and gets concentrated in the brain showing alterations in multiple brain regions such as thalamus, prefrontal cortex and cerebellum [52,53]. Within the brain, nicotine binds with nicotinic acetylcholine receptor (nAChRs) and disturbs cholinergic system, neuronal migration, synaptogenesis and neurotransmitter release. These nicotine induced adverse effects can alter the brain activity and produce neurobehavioral impairment such as cognitive effects, an influence of anxiety, analgesia or depression like behavior [54,55].

Nicotine causes significant loss of white matter and reduction in number of Purkinje cells of cerebellum, with possible predisposition to progressive impairment in the structural integrity and function of the cerebellum [56,57]. Though, nicotine causes postural imbalance, showing that nicotine might affect the circuitry involving the cerebellum in smokers [58]. Therefore, chronic exposure to nicotine negatively impacts the cerebellum, leading to impaired behavior and cognitive function.

The excessive production of free radicals and Reactive oxygen species (ROS) plays an important role in nicotine-induced brain (structural or neurobehavioral) alterations. The increased production of ROS and free radicals by nicotine can

produce a condition of oxidative stress which may cause cell death in various regions of the brain and memory impairments [59, 60]. These documents showed that cerebellum can be affected by nicotine.

BACOPA MONNIERI:

Medicinal plants are a pivotal reservoir of pharmacologically active compounds and have been used as a therapeutic medicine for several diseases since the ancient period. Recently, the interest in the use of medicinal plants has grown dramatically all around the world and almost 80,000 flowering plants are used for pharmaceutical purposes as per the International Union for Conservation of Nature (IUCN) report [61]. The World Health Organization (WHO) estimates that 80% of the world's population presently uses herbal medicine for some aspects of primary health care [62].

In Indian traditional medicine, *Bacopa-Monniери* (*BM*) is an important medicinal plant used in Ayurveda, a holistic system of medicine originating from India. It is a small perennial herbaceous plant commonly known as 'Brahmi' belonging to the family Scrophulariaceae [63]. *BM* is widely distributed in warmer and wetland region of the world, apart from India, Nepal, Vietnam, Sri Lanka and also found in Florida and other Southern states of USA [64]. It has been claimed as a nerve tonic and extremely used for the treatment of various neurological conditions (such as antidepressant, anxiolytic, anticonvulsant and antiparkinsonian) and also studies have shown to improve learning, memory and concentration [65, 66, 67]. It is also used in the repair of damaged neurons, neurological synthesis and restoration of synaptic activity and improves brain function [61].

Lacunae of the study:

There are numerous reports stating that arsenic or nicotine individually may lead to various health problems affecting different systems like reproductive, cardiovascular, respiratory, renal, digestive and nervous etc. The previous published reports also indicate that arsenic or nicotine individually can also impair the neurobehavioral activities such as cognition, learning and memory.

However, neurobehavioral, neurochemical and histomorphological changes in cerebellum due to arsenic or nicotine individually or in combination are not conclusive.

The previous studies have not established protective agent that reverses the alterations caused by arsenic or nicotine individually or in combination. In this view, an important Indian traditional medicinal plant; *Bacopa-Monnieiri* was used to assess its amelioration against the alterations caused by Arsenic or Nicotine individually or in combination.

Therefore, the present study was carried out in “ameliorative effect of *Bacopa-Monniери* on cerebellar toxicity caused by arsenic or nicotine individually or in combination of arsenic and nicotine in male Sprague-Dawley Rats.”



Objectives

RESEARCH QUESTIONS

- 1) Do Arsenic and Nicotine individually or in combination affect the Behavior, biochemical and Motor activities associated with Histomorphology of Cerebellum in Male Sprague-Dawley Rats?
- 2) Does *Bacopa-Monnieri* ameliorate the Arsenic and Nicotine individually or in combination induced Behavioral, biochemical and Motor activities associated with the Histomorphology of Cerebellum in Sprague-Dawley Rats?

AIM

To find the effect of Arsenic and Nicotine individually or in combination on the Biochemical, Behavioral, Motor and Histomorphology of cerebellum and the impact of *Bacopa-Monnieri* on these activities.

OBJECTIVES:

- 1) To assess the effect of Arsenic and Nicotine individually or in combination on Behavioral and Motor activities in male Sprague-Dawley rats
- 2) To estimate the biochemical changes in serum and cerebellum of Arsenic and Nicotine individually or in combined exposed rats
- 3) To investigate the Histomorphological effect of Arsenic, Nicotine and Co-exposure on rat cerebellum
- 4) To assess the concentration of arsenic and nicotine in Arsenic, Nicotine and Co-exposure induced rats
- 5) To determine the ameliorative effect of *Bacopa-Monnieri* on Arsenic, Nicotine and Co-exposure induced alterations in:-
 - a) Behavior and Motor activities
 - b) Oxidative stress markers
 - c) Histomorphological changes in cerebellum



Annexure-I

PUBLICATIONS

Paper Title	Authors	Journal	Indexation
Ameliorating Effect of Bacopa-Monnieri against Nicotine Induced Cerebellar Toxicity in Male Sprague-Dawley rats	Ravi Shankar Prasad Sawan¹ Sridevi NS ² Shashidhar K.N ³	Biomedical and Pharmacology Journal (BPJ). 2022; 15(2)	Scopus
Neurobehavioural and Neurochemical Changes in Arsenic Induced Cerebellar Toxicity in Male Sprague-Dawley Rats: An Experimental Study.	Ravi Shankar Prasad Sawan¹ Sridevi NS ² Shashidhar K.N ³	Journal of Clinical and Diagnostic Research. 2022; 16(3)	Web of Science

PRESENTATIONS

Title	Authors	Conference/ Webinar	Date
Behavioral and biochemical alterations in cerebellum of rats exposed to sodium Arsenite (Oral)	Ravi Shankar Prasad Sawan¹ Sridevi NS ² Shashidhar K.N ³	International conference- IVACON	20-22 nd Feb. 2022
Neurobehavioral and neurochemical changes in nicotine induced rat cerebellum (Oral)	Ravi Shankar Prasad Sawan¹ Sridevi NS ² Shashidhar K.N ³	National conference- AVEOCON	9-10 th July 2021



Annexure-II

IVACON 2021
INTERNATIONAL VIRTUAL ANATOMY CONFERENCE



**ANATOMICAL SOCIETY
of
KING GEORGE'S MEDICAL UNIVERSITY, U.P., LUCKNOW**

Certificate of Participation
RAVI SHANKAR PRASAD SAWAN

**gave an oral presentation during International Virtual Anatomy
Conference, organized by the Anatomical Society, King George's
Medical University UP, Lucknow, from 20-22 February 2021
entitled Behavioral and Biochemical alterations in cerebellum of
rats exposed to Sodium Arsenite**



		
Dr. Punita Manik	Dr. Anita Rani	Dr. A. K. Pankaj
ORGANISING CHAIRPERSON	ORGANISING SECRETARY	ORGANISING SECRETARY



Annexure-III





References

1. Waxman SG. Clinical Neuroanatomy: Fundamentals of the nervous system; McGraw Hill Education, 27th ed. 2013: pp 1-6.
2. Moore KL, Agur AMR, Dalley AF. Essentials of clinical Anatomy; Wolters Kluwer/ Lippincott Williams & Wilkins. 4th ed. 2011: 1-46.
3. Susan Standring. Gray's Anatomy- The Anatomical Basis of Clinical practice. ELSEVIER; 41st ed. 2016: pp 331-349.
4. Datta AK. Essentials of Human embryology. Current Books International. 6th ed. 2010:239-266.
5. Rapoport M, van Reekum R, Mayberg H. The role of the cerebellum in cognition and behavior: a selective review. J Neuropsychiatry Clin Neurosci. 2000 Spring; 12(2):193-198.
6. Stoodley CJ, Schmahmann JD. Evidence for topographic organization in the cerebellum of motor control versus cognitive and affective processing. Cortex. 2010; 46(7):831-844.
7. Schmahmann JD. The role of the cerebellum in cognition and emotion: personal reflections since 1982 on the dysmetria of thought hypothesis, and its historical evolution from theory to therapy. Neuropsychol Rev. 2010; 20(3):236-260.
8. Stoodley CJ, Valera EM, Schmahmann JD. Functional topography of the cerebellum for motor and cognitive tasks: an fMRI study. Neuroimage. 2012; 59(2):1560-1570.
9. Leiner HC. Solving the mystery of the human cerebellum. Neuropsychol Rev. 2010; 20(3):229-235.
10. Caplan LR, Pessin MS, Mohr JP. Vertebrobasilar occlusive disease. In: Bamett HJM, Mohr JP, Stein BM, Yatsu FM, editors. Stroke: pathophysiology, diagnosis and management. 2nd Ed. New York: Churchill Livingstone, 1992; 443:469-470

11. Garrison SJ, Rolack LA. Rehabilitation of the stroke patient. In: DeLisa JA, editor. Rehabilitation medicine: principles and practice. 2nd ed. Philadelphia: JB Lippincott and Company. 1993: 801-824.
12. Salman MS. Epidemiology of Cerebellar Diseases and Therapeutic Approaches. *Cerebellum*. 2018; 17(1):4-11.
13. Fogel BL. Childhood cerebellar ataxia. *J Child Neurol*. 2012; 27(9):1138-1145.
14. Manto M. Toxic agents causing cerebellar ataxias. *Handb Clin Neurol*. 2012; 103:201-213.
15. Javalkar V, Kelley RE, Gonzalez-Toledo E, McGee J, Minagar A. Acute ataxias: differential diagnosis and treatment approach. *Neurol Clin*. 2014; 32(4):881-891.
16. Landrigan PJ, Fuller R, Acosta NJR, Adeyi O, Arnold R, Basu NN et.al. The Lancet Commission on pollution and health. *Lancet*. 2018; 391(10119): 462-512.
17. Roy P, Saha A. Metabolism and toxicity of arsenic: A human carcinogen. *Current science*. 2002; 82(1):38-45.
18. Brinkel J, Khan MH, Kraemer A. A systematic review of arsenic exposure and its social and mental health effects with special reference to Bangladesh. *Int J Environ Res Public Health*. 2009; 6(5):1609-1619.
19. Verma C, Rohit B, Vinay P, Ashawat M. Arsenic induced diseases in human being, their diagnosis and treatment. *Journal of Chemical and Pharmaceutical Research*. 2016; 8(1):13-22.
20. Chouhan S, Flora SJ. Arsenic and fluoride: two major ground water pollutants. *Indian J Exp Biol*. 2010; 48(7):666-678.
21. Akter KF, Owens G, Davey DE, Naidu R. Arsenic speciation and toxicity in biological systems. *Rev Environ Contam Toxicol*. 2005; 184:97-149.

22. Ali H, Khan E, Ilahi I. Environmental chemistry and ecotoxicology of hazardous heavy metals: environmental persistence, toxicity, and bioaccumulation. *Journal of chemistry*. 2019; 2019:1-12.
23. Bloom MS, Surdu S, Neamtii IA, Gurzau ES. Maternal arsenic exposure and birth outcomes: a comprehensive review of the epidemiologic literature focused on drinking water. *Int J Hyg Environ Health*. 2014; 217(7):709-719.
24. Naujokas MF, Anderson B, Ahsan H, Aposhian HV, Graziano JH, Thompson C et.al. The broad scope of health effects from chronic arsenic exposure: update on a worldwide public health problem. *Environ Health Perspect*. 2013; 121(3):295-302.
25. Cherry JA, Shaikh AU, Tallman DE, Nicholson RV. Arsenic species as an indicator of redox conditions in groundwater, *Journal of Hydrology*, 2016, 43(1): 373-392.
26. Ghosh P, Basu A, Mahata J, Basu S, Sengupta M, Das JK et.al. Cytogenetic damage and genetic variants in the individuals susceptible to arsenic-induced cancer through drinking water. *Int J Cancer*. 2006; 118(10):2470-2478.
27. Samad N, Jabeen S, Imran I, Zulfiqar I, Bilal K. Protective effect of gallic acid against arsenic-induced anxiety-/depression- like behaviors and memory impairment in male rats. *Metab Brain Dis*. 2019; 34(4):1091-1102.
28. Kuo CC, Moon KA, Wang SL, Silbergeld E, Navas-Acien A. The Association of Arsenic Metabolism with Cancer, Cardiovascular Disease, and Diabetes: A Systematic Review of the Epidemiological Evidence. *Environ Health Perspect*. 2017; 125(8):1-15.

29. Cholanians AB, Phan AV, Ditzel EJ, Camenisch TD, Lau SS, Monks TJ. From the Cover: Arsenic Induces Accumulation of α -Synuclein: Implications for Synucleinopathies and Neurodegeneration. *Toxicol Sci.* 2016; 153(2):271-281.
30. Kaler S, Dhar P, Bhattacharya A, Mehra RD. Preliminary morphological and immunohistochemical changes in rat hippocampus following postnatal exposure to sodium arsenite. *Toxicol Int.* 2013; 20(2):160-169.
31. Herrera A, Pineda J, Antonio MT. Toxic effects of perinatal arsenic exposure on the brain of developing rats and the beneficial role of natural antioxidants. *Environ Toxicol Pharmacol.* 2013; 36(1):73-79.
32. Tolins M, Ruchirawat M, Landrigan P. The developmental neurotoxicity of arsenic: cognitive and behavioral consequences of early life exposure. *Ann Glob Health.* 2014; 80(4):303-314.
33. Ríos R, Zarazúa S, Santoyo ME, Sepúlveda-Saavedra J, Romero-Díaz V, Jiménez V et.al. Decreased nitric oxide markers and morphological changes in the brain of arsenic-exposed rats. *Toxicology.* 2009; 261(1-2):68-75.
34. Namgung U, Xia Z. Arsenic induces apoptosis in rat cerebellar neurons via activation of JNK3 and p38 MAP kinases. *Toxicol Appl Pharmacol.* 2001; 174(2):130-138.
35. Rodríguez VM, Carrizales L, Jiménez-Capdeville ME, Dufour L, Giordano M. The effects of sodium arsenite exposure on behavioral parameters in the rat. *Brain Res Bull.* 2001; 55(2):301-318.
36. World Health Organization. WHO Global Report: Mortality Attributable to Tobacco, WHO, Geneva 2012, http://www.who.int/tobacco/publications/surveillance/rep_mortality_attributable/en/, accessed 7 March 2018).

37. Ray R, Schnoll RA, Lerman C. Nicotine dependence: biology, behavior, and treatment. *Annual Review of Medicine*. 2009; 60:247–260.
38. Centers for Disease Control Prevention (CDC), 2008. Fact sheet: health effects of cigarette smoking. *Smok. Tob. Use*.
39. US Department of Health and Human Services (USDHHS). The health consequences of smoking—50 years of progress: a report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014. 17.
40. Cho Y. Warnings on US cigarette packs not as effective as those in other countries [Internet]. The Conversation. Available from: <http://theconversation.com/warnings-on-us-cigarette-packs-not-as-effective-as-those-in-other-countries-78659>.
41. Benowitz NL. Pharmacology of nicotine: addiction and therapeutics. *Annual review of pharmacology and toxicology*. 1996; 280: 1173-1181.
42. Oyem JC, Odokuma EI. Histomorphological Effects of Nicotine on Selected Parts of the Brain of Adult Wistar Rats. *Galician medical journal*. 2018; 25(2):48-60.
43. Fagerström K, Eissenberg T. Dependence on tobacco and nicotine products: a case for product-specific assessment. *Nicotine Tob Res*. 2012; 14(11):1382-1390.
44. Pepper JK, Brewer NT. Electronic nicotine delivery system (electronic cigarette) awareness, use, reactions and beliefs: a systematic review. *Tobacco control*. 2014; 23(5):375-384.
45. World Health Organization, 2005. Advisory note: waterpipe tobacco smoking: health effects, research needs and recommended action by regulators [online].

- Available: http://whqlibdoc.who.int/publications/2005/9241593857_eng.pdf?ua=1 [Accessed 18 June 2014].
46. Tobacco Advisory Group of the Royal College of Physicians, 2007. Harm reduction in nicotine addiction: helping people who can't quit [online]. Available: <http://www.rcplondon.ac.uk/sites/default/files/documents/harm-reduction-nicotine-addiction.pdf> [Accessed 18 June 2014].
47. Newhouse PA, Potter A, Levin ED. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. *Drugs Aging*. 1997; 11(3):206-228.
48. Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. *Cochrane Database Syst Rev*. 2018; 5(5):1-176.
49. Tjonck JA, Goncalves R, Castaing N, Molimard M, Tovagliaro F, Titier K. Death related to nicotine replacement therapy: A case report. *Forensic Sci Int*. 2020; 309:1-4.
50. Alkam T, Nabeshima T. Molecular mechanisms for nicotine intoxication. *Neurochem Int*. 2019; 125:117-126.
51. Omotoso GO, Gbadamosi IT, Olajide OJ, Dada-Habeeb SO, Arogundade TT, Yawson EO. *Moringa oleifera* phytochemicals protect the brain against experimental nicotine-induced neurobehavioral disturbances and cerebellar degeneration. *Pathophysiology*. 2018; 25(1):57-62.
52. Benowitz NL. Nicotine addiction. *N Engl J Med*. 2010; 362(24):2295-2303.
53. Sutherland MT, Riedel MC, Flannery JS, Yanes JA, Fox PT, Stein EA et.al. Chronic cigarette smoking is linked with structural alterations in brain regions

- showing acute nicotinic drug-induced functional modulations. *Behav Brain Funct.* 2016; 12(1):16.
54. Hayase T. Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors. *BMC Pharmacol.* 2011; 11:1-11.
55. Herman AI, Sofuoglu M. Comparison of available treatments for tobacco addiction. *Curr Psychiatry Rep.* 2010; 12(5):433-440.
56. Chen WJ, Edwards RB, Romero RD, Parnell SE, Monk RJ. Long-term nicotine exposure reduces Purkinje cell number in the adult rat cerebellar vermis. *Neurotoxicol Teratol.* 2003; 25(3):329-334.
57. Tewari A, Hasan M, Sahai A, Sharma PK, Rani A, Agarwal AK. White core of cerebellum in nicotine treated rats-a histological study. *Journal of Anatomical Society of India.* 2010; 59(2):150-153.
58. Pereira CB, Strupp M, Holzleitner T, Brandt T. Smoking and balance: correlation of nicotine-induced nystagmus and postural body sway. *Neuroreport.* 2001; 12(6):1223-1226.
59. Sudheer AR, Muthukumaran S, Devipriya N, Menon VP. Ellagic acid, a natural polyphenol protects rat peripheral blood lymphocytes against nicotine-induced cellular and DNA damage in vitro: with the comparison of N-acetylcysteine. *Toxicology.* 2007; 230(1):11-21.
60. Sirasanagandla SR, Rooben RK, Rajkumar, Narayanan SN, Jetti R. Ascorbic Acid ameliorates nicotine exposure induced impaired spatial memory performances in rats. *West Indian Med J.* 2014; 63(4):318-324.
61. Jeyasri R, Muthuramalingam P, Suba V, Ramesh M, Chen JT. *Bacopa monnieri* and Their Bioactive Compounds Inferred Multi-Target Treatment

- Strategy for Neurological Diseases: A Cheminformatics and System Pharmacology Approach. *Biomolecules*. 2020; 10(4):1-19.
62. W.H.O., Traditional Medicine, Fact Sheet, World Health Organization, Geneva, Switzerland, no. 134, 2003.
63. Pushkar GK, Pushkar BK, Sivabalan R. A review on major bioactivities of *Bacopa monnieri*. *Annals Appl. Biosci*. 2015; 2(2):1-11.
64. Russo A, Borrelli F. *Bacopa monniera*, a reputed nootropic plant: an overview. *Phytomedicine*. 2005; 12(4):305-317.
65. Gohil KJ, Patel JA. A review on *Bacopa monniera*: Current research and future prospects. *International Journal of Green Pharmacy*. 2010; 4(2):1-10.
66. Jyoti A, Sharma D. Neuroprotective role of *Bacopa monniera* extract against aluminium-induced oxidative stress in the hippocampus of rat brain. *Neurotoxicology*. 2006; 27(4):451-457.
67. Ramasamy S, Chin SP, Sukumaran SD, Buckle MJ, Kiew LV, Chung LY. In Silico and In Vitro Analysis of Bacoside A Aglycones and Its Derivatives as the Constituents Responsible for the Cognitive Effects of *Bacopa monnieri*. *PLoS One*. 2015; 10(5):1-19.
68. Mandal BK, Suzuki KT. Arsenic round the world: a review. *Talanta*. 2002; 58(1):201-235.
69. Holcomb N, Goswami M, Han SG, Scott T, D'Orazio J, Orren DK et.al. Inorganic arsenic inhibits the nucleotide excision repair pathway and reduces the expression of XPC. *DNA Repair (Amst)*. 2017; 52:70-80.
70. Oyagbemi AA, Omobowale TO, Asenuga ER, Ochigbo GO, Adejumobi AO, Adedapo AA et.al. Sodium arsenite-induced cardiovascular and renal dysfunction

- in rat via oxidative stress and protein kinase B (Akt/PKB) signaling pathway. *Redox Rep.* 2017; 22(6):467-477.
71. WHO. Guidelines for drinking-water quality, 3rd edition incorporating 1st and 2nd addenda. Vol. 1. Recommendations. Geneva, World Health Organization. 2008; pp. 306–308.
72. Harrison JW, Packman EW, Abbott DD. Acute oral toxicity and chemical and physical properties of arsenic trioxides. *AMA Arch Ind Health.* 1958; 17(2):118-123.
73. Lokuge KM, Smith W, Caldwell B, Dear K, Milton AH. The effect of arsenic mitigation interventions on disease burden in Bangladesh. *Environ Health Perspect.* 2004; 112(11):1172-1177.
74. Ko RJ. Causes, epidemiology, and clinical evaluation of suspected herbal poisoning. *J Toxicol Clin Toxicol.* 1999; 37(6):697-708.
75. Leslie AC, Smith H. Self-poisoning by the abuse of arsenic containing tonics. *Med Sci Law.* 1978; 18(3):159-162.
76. Chen HW. Gallium, indium, and arsenic pollution of groundwater from a semiconductor manufacturing area of Taiwan. *Bull Environ Contam Toxicol.* 2006; 77(2):289-296.
77. Cohen SM, Arnold LL, Eldan M, Lewis AS, Beck BD. Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment. *Crit Rev Toxicol.* 2006; 36(2):99-133.
78. Karim MM. Arsenic in groundwater and health problems in Bangladesh. *Water Research.* 2000; 34(1):304-310.
79. Schoolmeester WL, White DR. Arsenic poisoning. *South Med J.* 1980; 73(2):198-208.

80. Fowler BA, Woods JS. The effects of prolonged oral arsenate exposure on liver mitochondria of mice: morphometric and biochemical studies. *Toxicol Appl Pharmacol.* 1979; 50(2):177-187.
81. Vahter M. Mechanisms of arsenic biotransformation. *Toxicology.* 2002;181: 211-217.
82. Biggs ML, Kalman DA, Moore LE, Hopenhayn-Rich C, Smith MT, Smith AH. Relationship of urinary arsenic to intake estimates and a biomarker of effect, bladder cell micronuclei. *Mutat Res.* 1997; 386(3):185-195.
83. Thomas DJ, Styblo M, Lin S. The cellular metabolism and systemic toxicity of arsenic. *Toxicol Appl Pharmacol.* 2001; 176(2):127-144.
84. Le XC, Ma M, Cullen WR, Aposhian HV, Lu X, Zheng B. Determination of monomethylarsonous acid, a key arsenic methylation intermediate, in human urine. *Environ Health Perspect.* 2000; 108(11):1015-1018
85. Styblo M, Thomas DJ. In vitro inhibition of glutathione reductase by arsenotriglutathione. *Biochem Pharmacol.* 1995; 49(7):971-977.
86. Vahter M. Methylation of inorganic arsenic in different mammalian species and population groups. *Sci Prog.* 1999; 82(1):69-88.
87. Ali N, Hoque MA, Haque A, Salam KA, Karim MR, Rahman A et.al. Association between arsenic exposure and plasma cholinesterase activity: a population based study in Bangladesh. *Environ Health.* 2010; 9(1):1-9.
88. Styblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse EL, Hamilton GA et.al. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. *Arch Toxicol.* 2000; 74(6):289-299.

89. Taheri Zadeh Z, Esmaeilpour K, Aminzadeh A, Heidari MR, Joushi S. Resveratrol Attenuates Learning, Memory, and Social Interaction Impairments in Rats Exposed to Arsenic. *Biomed Res Int.* 2021; 2021:1-13.
90. Peruru R, Dodoala S. Therapeutic potential of diosmin, a citrus flavonoid against arsenic-induced neurotoxicity via suppression of NOX 4 and its subunits. *Indian J Pharmacol.* 2021; 53(2):132-142.
91. Peruru R, Usha Rani R, Thatiparthi J, Sampathi S, Dodoala S, Prasad KVSRG. Devil's claw (*Harpagophytum procumbens*) ameliorates the neurobehavioral changes and neurotoxicity in female rats exposed to arsenic. *Heliyon.* 2020; 6(5):1-8
92. Adedara IA, Fabunmi AT, Ayenitaju FC, Atanda OE, Adebowale AA, Ajayi BO et.al. Neuroprotective mechanisms of selenium against arsenic-induced behavioral impairments in rats. *Neurotoxicology.* 2020; 76:99-110.
93. Saritha S, Davuljigari CB, Kumar KP, Reddy GR. Effects of combined arsenic and lead exposure on the brain monoaminergic system and behavioral functions in rats: Reversal effect of MiADMSA. *Toxicol Ind Health.* 2019; 35(2):89-108.
94. Firdaus F, Zafeer MF, Ahmad M, Afzal M. Anxiolytic and anti-inflammatory role of thymoquinone in arsenic-induced hippocampal toxicity in Wistar rats. *Heliyon.* 2018; 4(6):1-22.
95. Goudarzi M, Amiri S, Nesari A, Hosseinzadeh A, Mansouri E, Mehrzadi S. The possible neuroprotective effect of ellagic acid on sodium arsenate-induced neurotoxicity in rats. *Life Sci.* 2018; 198:38-45.
96. Bikashvili T, Lordkipanidze T, Gogichaishvili N, Pochkhidze N. Effect of arsenic exposure on behavior of rats of various age groups. *Georgian Med News.* 2017; 264:119-126.

97. Sárközi K, Horváth E, Vezér T, Papp A, Paulik E. Behavioral and general effects of subacute oral arsenic exposure in rats with and without fluoride. *Int J Environ Health Res.* 2015; 25(4):418-431.
98. Chang CY, Guo HR, Tsai WC, Yang KL, Lin LC, Cheng TJ et.al. Subchronic Arsenic Exposure Induces Anxiety-Like Behaviors in Normal Mice and Enhances Depression-Like Behaviors in the Chemically Induced Mouse Model of Depression. *Biomed Res Int.* 2015; 2015:1-13.
99. Yadav RS, Sankhwar ML, Shukla RK, Chandra R, Pant AB, Islam F et.al. Attenuation of arsenic neurotoxicity by curcumin in rats. *Toxicol Appl Pharmacol.* 2009; 240(3):367-376.
100. Imosemi IO. Aqueous Extracts of *Daucus Carota* (Linn) Protected the Postnatal Developing Cerebellum of Wistar Rats Against Arsenic-Induced Oxidative Stress. *Niger J Physiol Sci.* 2021; 36(2):211-220.
101. Kuzu M, Kandemir FM, Yıldırım S, Çağlayan C, Küçükler S. Attenuation of sodium arsenite-induced cardiotoxicity and neurotoxicity with the antioxidant, anti-inflammatory, and antiapoptotic effects of hesperidin. *Environ Sci Pollut Res Int.* 2021; 28(9):10818-10831.
102. Azubuike-Osu SO, Famurewa AC, David JC, Abi I, Ogbu PN, Oparaji CK et.al. Virgin Coconut Oil Resists Arsenic-Induced Cerebral Neurotoxicity and Cholesterol Imbalance via Suppression of Oxidative Stress, Adenosine Deaminase and Acetylcholinesterase Activities in Rats. *Natural Product Communications.* 2021; 16(6):1-8.
103. Durappanavar PN, Nadoor P, Waghe P, Pavithra BH, Jayaramu GM. Melatonin Ameliorates Neuropharmacological and Neurobiochemical Alterations

- Induced by Subchronic Exposure to Arsenic in Wistar Rats. *Biol Trace Elem Res.* 2019; 190(1):124-139.
104. Arslan-Acaroz D, Zemheri F, Demirel HH, Kucukkurt I, Ince S, Eryavuz A. In vivo assessment of polydatin, a natural polyphenol compound, on arsenic-induced free radical overproduction, gene expression, and genotoxicity. *Environ Sci Pollut Res Int.* 2018; 25(3):2614-2622.
105. Guan H, Li S, Guo Y, Liu X, Yang Y, Guo J et.al. Subchronic Exposure to Arsenic Represses the TH/TR β 1-CaMK IV Signaling Pathway in Mouse Cerebellum. *Int J Mol Sci.* 2016; 17(2):1-16.
106. Ding X, Su Q, Jiang M, Xie H, Cong J, Wang L. Arsenic affects on cerebellar development of mice. *Toxicol Mech Methods.* 2013; 23(9):672-677.
107. Yildiz D. Nicotine, its metabolism and an overview of its biological effects. *Toxicon.* 2004; 43(6):619-632.
108. Sobkowiak R, Lesicki A. Absorption, metabolism and excretion of nicotine in humans. *Postepy Biochemii.* 2013; 59(1):33-44.
109. Jacob P 3rd, Yu L, Liang G, Shulgin AT, Benowitz NL. Gas chromatographic-mass spectrometric method for determination of anabasine, anatabine and other tobacco alkaloids in urine of smokers and smokeless tobacco users. *J Chromatogr.* 1993; 619(1):49-61.
110. Iranloye BO, Bolarinwa AF. Effect of nicotine administration on weight and histology of some vital visceral organs in female albino rats. *Niger J Physiol Sci.* 2009; 24(1):7-12.
111. O'Neil MJ, Smith A, Heckelman PE, Budavari S. The Merck Index-An Encyclopedia of Chemicals, Drugs, and Biologicals. Whitehouse Station, NJ: Merck and Co. Inc. 2001; 767:4342.

112. Boublík T, Fried V, Hála E. The vapour pressures of pure substances. 1984.
113. Lide DR. CRC Handbook of Chemistry and Physics 89th Edition 2008–2009. CRC Press, Taylor & Francis, Boca Raton, FL; 2008.
114. Tomizawa M, Casida JE. Neonicotinoid insecticide toxicology: mechanisms of selective action. *Annu Rev Pharmacol Toxicol*. 2005; 45:247-268.
115. Valentine G, Sofuoglu M. Cognitive Effects of Nicotine: Recent Progress. *Curr Neuropharmacol*. 2018; 16(4):403-414.
116. Chaturvedi P, Mishra A, Datta S, Sinukumar S, Joshi P, Garg A. Harmful effects of nicotine. *Indian Journal of Medical and Paediatric Oncology*. 2015; 36(1):24-31.
117. Gori GB, Benowitz NL, Lynch CJ. Mouth versus deep airways absorption of nicotine in cigarette smokers. *Pharmacol Biochem Behav*. 1986; 25(6):1181-1184.
118. Armitage A, Dollery C, Houseman T, Kohner E, Lewis PJ, Turner D. Absorption of nicotine from small cigars. *Clin Pharmacol Ther*. 1978; 23(2):143-151.
119. Benowitz NL, Iii PJ. Daily intake of nicotine during cigarette smoking. *Clinical Pharmacology & Therapeutics*. 1984; 35(4):499-504.
120. Benowitz NL. Clinical pharmacology of inhaled drugs of abuse: implications in understanding nicotine dependence. *NIDA Res Monogr*. 1990; 99:12-29.
121. Benowitz NL, Jacob Iii P, Savanapridi C. Determinants of nicotine intake while chewing nicotine polacrilex gum. *Clinical Pharmacology & Therapeutics*. 1987; 41(4):467-473.
122. West R, Hajek P, Foulds J, Nilsson F, May S, Meadows A. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. *Psychopharmacology (Berl)* 2000; 149(3):198–202.

123. McBride JS, Altman DG, Klein M, White W. Green tobacco sickness. *Tob Control* 1998;7(3):294–298.
124. Fant RV, Henningfield JE, Shiffman S, Strahs KR, Reitberg DP. A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. *Pharmacology Biochemistry and Behavior*. 2000; 67(3):479-482.
125. Benowitz NL, Jacob P 3rd, Jones RT, Rosenberg J. Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. *J Pharmacol Exp Ther*. 1982; 221(2):368–372.
126. Urakawa N, Nagata T, Kudo K, Kimura K, Imamura T. Simultaneous determination of nicotine and cotinine in various human tissues using capillary gas chromatography/mass spectrometry. *International journal of legal medicine*. 1994; 106(5):232-236.
127. Perry DC, Dávila-García MI, Stockmeier CA, Kellar KJ. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. *J Pharmacol Exp Ther*. 1999; 289(3):1545-1552.
128. Rose JE, Behm FM, Westman EC, Coleman RE. Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction. *Drug Alcohol Depend*. 1999; 56(2): 99–107.
129. Lunell E, Molander L, Ekberg K, Wahren J. Site of nicotine absorption from a vapour inhaler--comparison with cigarette smoking. *Eur J Clin Pharmacol*. 2000; 55(10):737-741.
130. Kyerematen GA, Vesell ES. Metabolism of nicotine. *Drug Metab Rev*. 1991; 23(1-2):3-41.

131. Park SB, Jacob Iii P, Benowitz NL, Cashman JR. Stereoselective metabolism of [S]-[-]-nicotine in humans: Formation of trans-[S]-[-]-nicotine N-1'-oxide. *Chemical research in toxicology*. 1993; 6(6):880-888.
132. Cashman JR, Park SB, Yang ZC, Wrighton SA, Jacob Iii P, Benowitz NL. Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N'-oxide. *Chemical research in toxicology*. 1992; 5(5):639-46.
133. Gorrod JW. The mammalian metabolism of nicotine: an overview. *Nicotine and related Alkaloids*: Springer; 1993. p. 31-43.
134. Molander L, Hansson A, Lunell E. Pharmacokinetics of nicotine in healthy elderly people. *Clinical Pharmacology & Therapeutics*. 2001; 69(1):57-65.
135. Balabanova S, Bühler G, Schneider E, Boschek HJ, Schneitler H. Über die Ausscheidung von Nikotin mit dem apokrinen und ekkrinen Schweiß bei Rauchern und Passiv-Rauchern [Nicotine excretion by the apocrine and eccrine sweat in smokers and passive smokers]. *Hautarzt*. 1992; 43(2):73-76.
136. Seaton MJ, Kyerematen GA, Vesell ES. Rates of excretion of cotinine, nicotine glucuronide, and 3-hydroxycotinine glucuronide in rat bile. *Drug Metab Dispos*. 1993; 21(5):927-932.
137. Benowitz NL, Hukkanen J, Jacob P. *Nicotine Chemistry, Metabolism, Kinetics and Biomarkers*. Springer Berlin Heidelberg. p. 29-60.
138. Motaghinejad M, Motevalian M, Fatima S, Faraji F, Mozaffari S. The Neuroprotective Effect of Curcumin Against Nicotine-Induced Neurotoxicity is Mediated by CREB-BDNF Signaling Pathway. *Neurochem Res*. 2017; 42(10):2921-2932.

139. Kandeil MA, Mohammed ET, Radi RA, Khalil F, Abdel-Razik AH, Abdel-Daim MM et.al. Nanonaringenin and Vitamin E Ameliorate Some Behavioral, Biochemical, and Brain Tissue Alterations Induced by Nicotine in Rats. *J Toxicol.* 2021; 2021:1-15.
140. Raeeszadeh M, Mortazavi P, Atashin-Sadafi R. The Antioxidant, Anti-Inflammatory, Pathological, and Behavioural Effects of *Medicago sativa* L. (Alfalfa) Extract on Brain Injury Caused by Nicotine in Male Rats. *Evid Based Complement Alternat Med.* 2021; 2021:1-9.
141. Bashiri H, Rezayof A, Sahebgharani M, Tavangar SM, Zarrindast MR. Modulatory effects of the basolateral amygdala $\alpha 2$ -adrenoceptors on nicotine-induced anxiogenic-like behaviours of rats in the elevated plus maze. *Neuropharmacology.* 2016; 105:478-486.
142. Ajarem JS, Al-Basher G, Allam AA, Mahmoud AM. *Camellia sinensis* Prevents Perinatal Nicotine-Induced Neurobehavioral Alterations, Tissue Injury, and Oxidative Stress in Male and Female Mice Newborns. *Oxid Med Cell Longev.* 2017; 2017:1-17.
143. Ijomone OM, Olaibi OK, Biose IJ, Mba C, Umoren KE, Nwoha PU. Performance of motor associated behavioural tests following chronic nicotine administration. *Ann Neurosci.* 2014; 21(2):42-46.
144. Budzynska B, Boguszevska-Czubara A, Kruk-Slomka M, Skalicka-Wozniak K, Michalak A, Musik I et.al. Effects of imperatorin on nicotine-induced anxiety- and memory-related responses and oxidative stress in mice. *Physiol Behav.* 2013; 122:46-55.

145. Falco AM, McDonald CG, Bachus SE, Smith RF. Developmental alterations in locomotor and anxiety-like behavior as a function of D1 and D2 mRNA expression. *Behav Brain Res.* 2014; 260:25-33.
146. Elgayar SAM, Hussein OA, Mubarak HA, Ismaiel AM, Gomaa AMS. Nicotine impact on rat substantia nigra compacta. *Anat Cell Biol.* 2021; 54(1):112-123.
147. Elsonbaty SM, Ismail AFM. Nicotine encourages oxidative stress and impairment of rats' brain mitigated by *Spirulina platensis* lipopolysaccharides and low-dose ionizing radiation. *Arch Biochem Biophys.* 2020; 689:1-43.
148. Saad AB, Rjeibi I, Brahmi N, Elaloui E, Zouari N. Nicotine-induced oxidative stress, testis injury, AChE inhibition and brain damage alleviated by *Mentha spicata*. *Inflammopharmacology.* 2020; 28(4):939-948.
149. Motaghinejad M, Farokhi N, Motevalian M, Safari S. Molecular, histological and behavioral evidences for neuroprotective effects of minocycline against nicotine-induced neurodegeneration and cognition impairment: Possible role of CREB-BDNF signaling pathway. *Behav Brain Res.* 2020; 386:1-13.
150. Oyeyipo IP, Raji Y, Bolarinwa AF. Nicotine alters serum antioxidant profile in male albino rats. *N Am J Med Sci.* 2014; 6(4):168-171.
151. Das S, Gautam N, Dey SK, Maiti T, Roy S. Oxidative stress in the brain of nicotine-induced toxicity: protective role of *Andrographis paniculata* Nees and vitamin E. *Appl Physiol Nutr Metab.* 2009; 34(2):124-135.

152. Tewari A, Hasan M, Sahai A, Sharma PK, Agarwal AK. Nicotine mediated microcystic oedema in white matter of cerebellum: possible relationship to postural imbalance. *Ann Neurosci*. 2011; 18(1):14-16.
153. Omotoso GO, Babalola FA. Histological changes in the cerebelli of adult wistar rats exposed to cigarette smoke. *Nigerian Journal of Physiological Sciences*. 2014; 29(1):43-46.
154. Augustine IO, Gertrude ON, Loveth AN, Al-Rashed S, Obinna UO, Uchenna EK et.al. The role of Garlic and Honey on Nicotine-Induced Toxicity on the Cerebellum of adult Wistar Rats. 2020.1-18.
155. Bammidi SR, Volluri SS, Chippada SC, Avanigadda S, Vangalapati M. A review on pharmacological studies of Bacopa monniera. *Journal of Chemical, Biological and Physical Sciences*. 2011; 1(2):250-259.
156. Mathur D, Goyal K, Koul V, Anand A. The Molecular Links of Re-Emerging Therapy: A Review of Evidence of Brahmi (*Bacopa monniera*). *Front Pharmacol*. 2016; 7:1-15.
157. Mukherjee GD, Dey CD. Clinical trial on Brahmi. I. *J Exp Med Sci*. 1966; 10(1):5-11.
158. Ernst E. Herbal remedies for anxiety - a systematic review of controlled clinical trials. *Phytomedicine*. 2006; 13(3):205-208.
159. Sinha S, Saxena R. Effect of iron on lipid peroxidation, and enzymatic and non-enzymatic antioxidants and bacoside-A content in medicinal plant *Bacopa monnieri* L. *Chemosphere*. 2006; 62(8):1340-1350.
160. Shakoor A, Akram M, Asharaf CM, Siddiqui MR. Pharmacognostic study and chemical/pharmacological evaluation of Brahmi-buti. *Hamdard Medicus*. 1994; 37: 92-109.

161. Christinal J, Sumathi T. Effect of *Bacopa monniera* extract on methylmercury-induced behavioral and histopathological changes in rats. *Biol Trace Elem Res.* 2013; 155(1):56-64.
162. Krishna G, Hosamani R, Muralidhara. *Bacopa monnieri* Supplements Offset Paraquat-Induced Behavioral Phenotype and Brain Oxidative Pathways in Mice. *Cent Nerv Syst Agents Med Chem.* 2019; 19(1):57-66.
163. Sumathi T, Shobana C, Christinal J, Anusha C. Protective effect of *Bacopa monniera* on methyl mercury-induced oxidative stress in cerebellum of rats. *Cell Mol Neurobiol.* 2012; 32(6):979-987.
164. Banerjee R, Hazra S, Ghosh AK, Mondal AC. Chronic administration of *bacopa monniera* increases BDNF protein and mRNA expressions: a study in chronic unpredictable stress induced animal model of depression. *Psychiatry Investig.* 2014; 11(3):297-306.
165. Saini N, Singh D, Sandhir R. *Bacopa monnieri* prevents colchicine-induced dementia by anti-inflammatory action. *Metab Brain Dis.* 2019; 34(2):505-518.
166. Velaga MK, Basuri CK, Robinson Taylor KS, Yallapragada PR, Rajanna S, Rajanna B. Ameliorative effects of *Bacopa monniera* on lead-induced oxidative stress in different regions of rat brain. *Drug Chem Toxicol.* 2014; 37(3):357-364.
167. Mondal P, Trigun SK. *Bacopa monnieri* Extract (CDRI-08) Modulates the NMDA Receptor Subunits and nNOS-Apoptosis Axis in Cerebellum of Hepatic Encephalopathy Rats. *Evid Based Complement Alternat Med.* 2015; 2015:1-9.
168. Packyanathan JS, Gayathri R, Vishnupriya V. Preliminary phytochemical analysis and cytotoxicity potential of *Bacopa monnieri* on oral cancer cell lines. *Int J Pharm Sci Rev Res.* 2016; 39:4-8.

169. Patnaik A, Sharma HP, Fatma B, Anita RA, Jain P, Basri F. Phyto-chemical Screening of some medicinal plants used by the ethnic communities of Jharkhand state. *Int. Jou. Bio. Sci. and Eng.* 2012; 3(3):203-9.
170. Zimcikova E, Simko J, Karesova I, Kremlacek J, Malakova J. Behavioral effects of antiepileptic drugs in rats: Are the effects on mood and behavior detectable in open-field test? *Seizure.* 2017; 52:35-40.
171. Fan SJ, Jiang H, Yang LJ, Liu X, Song J, Pan F. Effects of adrenergic agents on stress-induced brain microstructural and immunochemical changes in adult male Wistar rats. *Ann Anat.* 2011; 193(5):418-424.
172. Pellow S, File SE. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. *Pharmacol Biochem Behav.* 1986; 24(3):525-529.
173. Silveira EMS, Kroth A, Santos MCQ, Silva TCB, Silveira D, Riffel APK et.al. Age-related changes and effects of regular low-intensity exercise on gait, balance, and oxidative biomarkers in the spinal cord of Wistar rats. *Braz J Med Biol Res.* 2019; 52(7):1-13.
174. Lefèvre G, Beljean-Leymarie M, Beyerle F, Bonnefont-Rousselot D, Cristol JP, Thérond P et.al. Evaluation of lipid peroxidation by measuring thiobarbituric acid reactive substances]. *Ann Biol Clin (Paris).* 1998; 56(3):305-19.
175. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. *Anal Biochem.* 1982; 126(1):131-138.
176. Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. Selenium: biochemical role as a component of glutathione peroxidase. *Science.* 1973; 179(4073):588-590.

177. Ballentine R, Burford DD. Determination of metals. *Methods Enzymol.* 1957; 3, 1002–1035.
178. Alhusban AA, Ata SA. Simple HPLC method for rapid quantification of nicotine content in e-cigarettes liquids. *Acta Chromatographica.* 2021; 33(3):302-307.
179. Shafri MAM, Jais AMM, Jaffri JM, Kim MK, Ithnin H, Mohamed F. Cresyl violet staining to assess neuroprotective and neuroregenerative effects of haruan traditional extract against neurodegenerative damage of ketamine. *International Journal of Pharmacy and Pharmaceutical Sciences.* 2012; 4(4):163-168.
180. Gaire BP, Kwon OW, Park SH, Chun KH, Kim SY, Shin DY et.al.. Neuroprotective effect of 6-paradol in focal cerebral ischemia involves the attenuation of neuroinflammatory responses in activated microglia. *PLoS One.* 2015; 10(3):1-17.
181. Jha P, Chaloupka FJ, Corrao M, Jacob B. Reducing the burden of smoking world- wide: effectiveness of interventions and their coverage. *Drug and alcohol review.* 2006; 25(6):597-609.
182. Bachmanov AA, Reed DR, Tordoff MG, Price RA, Beauchamp GK. Nutrient preference and diet-induced adiposity in C57BL/6ByJ and 129P3/J mice. *Physiol Behav.* 2001; 72(4):603-613.
183. Smith BK, Andrews PK, West DB. Macronutrient diet selection in thirteen mouse strains. *Am J Physiol Regul Integr Comp Physiol.* 2000; 278(4):R797-805.
184. Hasan M, Awal MA, Ara A, Rashid MB, Azam MG, Ali MH. Study on prevention of induced arsenic toxicity in rats by using spirulina and thankuni. *Scholars J Appl Med Sci.* 2015; 3(2D):828-32.

185. Durappanavar PN, Nadoor P, Waghe P, Pavithra BH, Jayaramu GM. Melatonin Ameliorates Neuropharmacological and Neurobiochemical Alterations Induced by Subchronic Exposure to Arsenic in Wistar Rats. *Biol Trace Elem Res.* 2019; 190(1):124-139.
186. Jain A, Agrawal S, Flora SJS. Arsenic and nicotine co-exposure lead to some synergistic effects on oxidative stress and apoptotic markers in young rat blood, liver, kidneys and brain. *Toxicol Rep.* 2015; 2:1334-1346.
187. Liu S, Willett WC, Manson JE, Hu FB, Rosner B, Colditz G. Relation between changes in intakes of dietary fiber and grain products and changes in weight and development of obesity among middle-aged women. *The American journal of clinical nutrition.* 2003; 78(5):920-927.
188. Frankish HM, Dryden S, Wang Q, Bing C, MacFarlane IA, Williams G. Nicotine administration reduces neuropeptide Y and neuropeptide Y mRNA concentrations in the rat hypothalamus: NPY may mediate nicotine's effects on energy balance. *Brain Res.* 1995; 694(1-2):139-146.
189. Winders SE, Grunberg NE. Effects of nicotine on body weight, food consumption and body composition in male rats. *Life Sci.* 1990; 46(21):1523-1530.
190. Maritz GS. Maternal nicotine exposure and carbohydrate metabolism of fetal and neonatal lung tissue: response to nicotine withdrawal. *Respiration.* 1987; 51(3):232-240
191. AlBasher G, Abdel-Daim MM, Almeer R, Ibrahim KA, Hamza RZ, Bungau S et.al. Synergistic antioxidant effects of resveratrol and curcumin against fipronil-triggered oxidative damage in male albino rats. *Environ Sci Pollut Res Int.* 2020; 27(6):6505-6514.

192. Ashok I, Sheeladevi R. Biochemical responses and mitochondrial mediated activation of apoptosis on long-term effect of aspartame in rat brain. *Redox Biol.* 2014; 2:820-831.
193. Bidlack, Wayne R. Phytochemicals a new paradigm. Lancaster, Technomic Publishers, *Food Toxicology*. 1998:179:77-96.
194. Baglole CJ, Sime PJ, Phipps RP. Cigarette smoke-induced expression of heme oxygenase-1 in human lung fibroblasts is regulated by intracellular glutathione. Am J Stohs SJ, Bagchi D. Oxidative mechanisms in the toxicity of metal ions. *Free Radic Biol Med.* 1995; 18(2):321-336.
195. Stohs SJ, Bagchi D. Oxidative mechanisms in the toxicity of metal ions. *Free Radic Biol Med.* 1995; 18(2):321-336.
196. Pompella A, Romani A, Benedetti A, Comporti M. Loss of membrane protein thiols and lipid peroxidation in allyl alcohol hepatotoxicity. *Biochem Pharmacol.* 1991; 41(8):1255-1259.
197. Alizadeh-Ghodsi M, Zavvari A, Ebrahimi-Kalan A, Shiri-Shahsavari MR, Yousefi B. The hypothetical roles of arsenic in multiple sclerosis by induction of inflammation and aggregation of tau protein: A commentary. *Nutr Neurosci.* 2018; 21(2):92-96.
198. Dhanasekaran M, Tharakan B, Holcomb LA, Hitt AR, Young KA, Manyam BV. Neuroprotective mechanisms of ayurvedic antidementia botanical *Bacopa monniera*. *Phytother Res.* 2007; 21(10):965-969.
199. Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S. Antioxidant activity of *Bacopa monniera* in rat frontal cortex, striatum and hippocampus. *Phytother Res.* 2000; 14(3):174-179.

200. Finnerty N, O'Riordan SL, Klamer D, Lowry J, Pålsson E. Increased brain nitric oxide levels following ethanol administration. *Nitric Oxide*. 2015; 47:52-57.
201. Lüth HJ, Münch G, Arendt T. Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. *Brain Res*. 2002; 953(1-2):135-143.
202. Anand A, Saraf MK, Prabhakar S. Antiamnesic effect of *B. monniera* on L-NNA induced amnesia involves calmodulin. *Neurochem Res*. 2010; 35(8):1172-1781.
203. Kalueff AV, Tuohimaa P. Experimental modeling of anxiety and depression. *Acta Neurobiol Exp (Wars)*. 2004; 64(4):439-448.
204. Donatti AF, Soriano RN, Leite-Panissi CR, Branco LG, de Souza AS. Anxiolytic-like effect of hydrogen sulfide (H₂S) in rats exposed and re-exposed to the elevated plus-maze and open field tests. *Neurosci Lett*. 2017; 642:77-85.
205. Umezu T, Nakamiya K, Kita K, Ochi T, Shibata Y, Morita M. Diphenylarsinic acid produces behavioral effects in mice relevant to symptoms observed in citizens who ingested polluted well water. *Neurotoxicology and teratology*. 2012; 34(1):143-151.
206. Benwell ME, Balfour DJ, Khadra LF. Studies on the influence of nicotine infusions on mesolimbic dopamine and locomotor responses to nicotine. *Clin Investig*. 1994; 72(3):233-239.
207. Davies KG, Ekpennyong C, Green O, Antai A, Osim E. Locomotor and exploratory behaviour in mice treated with oral artesunate. *British Journal of Science*. 2013; 8(1):47-57.
208. Venero C, Guadaño-Ferraz A, Herrero AI, Nordström K, Manzano J, de Escobar GM et.al. Anxiety, memory impairment, and locomotor dysfunction

- caused by a mutant thyroid hormone receptor $\alpha 1$ can be ameliorated by T3 treatment. *Genes Dev.* 2005; 19(18):2152-2163.
209. Polotow TG, Poppe SC, Vardaris CV, Ganini D, Guariroba M, Mattei R et.al. Redox Status and Neuro Inflammation Indexes in Cerebellum and Motor Cortex of Wistar Rats Supplemented with Natural Sources of Omega-3 Fatty Acids and Astaxanthin: Fish Oil, Krill Oil, and Algal Biomass. *Mar Drugs.* 2015; 13(10):6117-6137.
210. Fink JS, Smith GP. Relationships between selective denervation of dopamine terminal fields in the anterior forebrain and behavioral responses to amphetamine and apomorphine. *Brain Res.* 1980; 201(1):107-127.
211. Kaushal P, Kumar P, Dhar P. Ameliorative role of antioxidant supplementation on sodium-arsenite induced adverse effects on the developing rat cerebellum. *J Ayurveda Integr Med.* 2020; 11(4):455-463.
212. Zarrindast MR, Aghamohammadi-Sereshki A, Rezayof A, Rostami P. Nicotine-induced anxiogenic-like behaviours of rats in the elevated plus-maze: possible role of NMDA receptors of the central amygdala. *J Psychopharmacol.* 2012; 26(4):555-563.
213. Clarke PB, Kumar R. The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. *Br J Pharmacol.* 1983; 78(2):329-337.
214. Sachs BD. The development of grooming and its expression in adult animals. *Ann N Y Acad Sci.* 1988; 525:1-17.
215. Terry RL. Primate grooming as a tension reduction mechanism. *J Psychol.* 1970; 76(1):129-136.

216. Bandiera S, Caletti G, Giustina CLD, Hansen AW, Deniz BF, Confortim HD et.al. Changes in behavioral and neuronal parameters by alcohol, cigarette, or their combined use in rats. *Behav Pharmacol.* 2019; 30(6):490-499.
217. Clarke PBS, Kumar R. Characterization of the locomotor stimulant action of nicotine in tolerant rats. *Br J Pharmacol.* 1983; 80:587–594.
218. Iñiguez SD, Warren BL, Parise EM, Alcantara LF, Schuh B, Maffeo ML, Manojlovic Z, Bolaños-Guzmán CA. Nicotine exposure during adolescence induces a depression-like state in adulthood. *Neuropsychopharmacology.* 2009; 34(6):1609-1624.
219. Krishnakumar A, Nandhu MS, Paulose CS. Upregulation of 5-HT_{2C} receptors in hippocampus of pilocarpine-induced epileptic rats: antagonism by *Bacopa monnieri*. *Epilepsy Behav.* 2009; 16(2):225-230.
220. Abou-Donia MB, Abdel-Rahman A, Goldstein LB, Dechkovskaia AM, Shah DU, Bullman SL et.al. Sensorimotor deficits and increased brain nicotinic acetylcholine receptors following exposure to chlorpyrifos and/or nicotine in rats. *Archives of toxicology.* 2003; 77(8):452-458.



Conclusion

1. Results of the present study suggest that arsenic and nicotine individually or in combination of arsenic and nicotine could be considered as a cause of cerebellar toxicity in male Sprague-Dawley rats due to:
 - a) Increased oxidative stress in cerebellum
 - b) Reduction in locomotion
 - c) Increased anxiety
 - d) Loss of motor coordination and balance
 - e) Reduction in number of purkinje cells and shrinkage of purkinje cells
 - f) Alteration in thickness of molecular layer and granular layer of cerebellum
 - g) Reduction in cortical thickness at folium, fissure and base
2. Results of the present study also demonstrated that combined exposure of arsenic and nicotine reduced the body weight and brain weight.
3. Further, the present study may also suggest that *Bacopa-Monnieri* could be considered as a therapeutic agent against arsenic and /or nicotine treated male Sprague-Dawley rats due to:
 - a) Reduced oxidative stress
 - b) Improvement in locomotion
 - c) Reduced anxiety
 - d) Improvement in motor coordination and balance
 - e) Improvement in number of purkinje cells and cell shrinkage of Purkinje cells
4. The oral supplementation of *Bacopa-Monnieri* brought the body weight and brain weight to normal level which was altered due to arsenic and/or nicotine treated rats.

SUMMARY AND CONCLUSION

As shown the results, the present study conclude that arsenic and nicotine individually or a combination of arsenic and nicotine exposure followed by Bacopa-Monnieri treated rats indicated the protective influence of Bacopa-Monnieri in cerebellum of rats against arsenic and nicotine alone or a combination of arsenic and nicotine treated rats.

- Only selected markers and behavioral tests were evaluated
- Quantitative phytochemical analysis of *Bacopa-Monnieri* was not done
- Sample size is small in each group.



*New Knowledge
Generated*

1. Arsenic, nicotine and a combination of arsenic and nicotine treated rats reduced the body weight gain. Whereas Arsenic and nicotine individually and a combination of arsenic and nicotine exposure followed by *Bacopa-Monnieri* treated rats reduces the body weight loss caused by arsenic and nicotine individually or in combination of arsenic and nicotine treated rats.
2. Arsenic and/or nicotine significantly increases the oxidative stress in serum and cerebellum of rats. *Bacopa-Monnieri* treated rats significantly reduces the oxidative stress in serum and cerebellum of rats.
3. Arsenic and nicotine individually or a combination of arsenic and nicotine treated rats showed anxiety like behaviors and alterations in motor coordination and balance as well as reduction in locomotion activities. Whereas, oral supplementation of *Bacopa-Monnieri* treated rats showed improvement in anxiety like behaviors, motor coordination and balance as well as increase in locomotion activities.
4. Reduction in number of purkinje cells, cell shrinkage as well as reduction in thickness of molecular layer and granular layer and also cortical thickness at folium, fissure and base was found in arsenic and nicotine individually or a combination of arsenic and nicotine treated rats. The oral supplementation of *Bacopa-Monnieri* reversed the alteration caused by arsenic and nicotine individually or combination of arsenic and nicotine treated rats.

As the human populations are also exposed to arsenic and nicotine and the effect produced on the rats can be linked to human populations due to their genetic, biological and behavioral characteristics with the rats.

Hence, *Bacopa-Monnieri* can be recommended to humans who are chronically exposed to arsenic and/or nicotine which will bring reversal effect produced by arsenic and/or nicotine.